Absci's ABS-201 anti-PRLR antibody trial begins with first healthy volunteers dosed.

Absci Corporation has initiated a Phase 1/2a clinical trial to evaluate the safety and efficacy of ABS-201, an anti-prolactin receptor antibody. The trial aims to assess safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of the antibody. Interim data are expected in the second half of 2026. The trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia and a Phase 2 trial for endometriosis.